JP2019533472A - Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略 - Google Patents

Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略 Download PDF

Info

Publication number
JP2019533472A
JP2019533472A JP2019524363A JP2019524363A JP2019533472A JP 2019533472 A JP2019533472 A JP 2019533472A JP 2019524363 A JP2019524363 A JP 2019524363A JP 2019524363 A JP2019524363 A JP 2019524363A JP 2019533472 A JP2019533472 A JP 2019533472A
Authority
JP
Japan
Prior art keywords
oligonucleotide
hbv
nucleotide
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533472A5 (enrdf_load_stackoverflow
Inventor
グリャズノフ，セルゲイ
フィッツジェラルド，メーガン
ディミトローヴァ ストイチェヴァ，アンチツサ
ディミトローヴァ ストイチェヴァ，アンチツサ
ホン，ジン
Original Assignee
ヤンセン バイオファーマ インク．
ヤンセン バイオファーマ インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオファーマ インク．, ヤンセン バイオファーマ インク． filed Critical ヤンセン バイオファーマ インク．
Publication of JP2019533472A publication Critical patent/JP2019533472A/ja
Publication of JP2019533472A5 publication Critical patent/JP2019533472A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019524363A 2016-11-11 2017-11-13 Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略 Pending JP2019533472A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662420801P 2016-11-11 2016-11-11
US62/420,801 2016-11-11
US201762558770P 2017-09-14 2017-09-14
US62/558,770 2017-09-14
PCT/US2017/061348 WO2018089914A1 (en) 2016-11-11 2017-11-13 Oligonucleotide targeting strategy for hbv cccdna

Publications (2)

Publication Number Publication Date
JP2019533472A true JP2019533472A (ja) 2019-11-21
JP2019533472A5 JP2019533472A5 (enrdf_load_stackoverflow) 2020-12-24

Family

ID=60452809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524363A Pending JP2019533472A (ja) 2016-11-11 2017-11-13 Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略

Country Status (10)

Country Link
US (1) US20180179542A1 (enrdf_load_stackoverflow)
EP (1) EP3538654A1 (enrdf_load_stackoverflow)
JP (1) JP2019533472A (enrdf_load_stackoverflow)
KR (1) KR20190076050A (enrdf_load_stackoverflow)
CN (1) CN110234763A (enrdf_load_stackoverflow)
AU (1) AU2017356221A1 (enrdf_load_stackoverflow)
CA (1) CA3043637A1 (enrdf_load_stackoverflow)
IL (1) IL266525A (enrdf_load_stackoverflow)
TW (1) TW201831684A (enrdf_load_stackoverflow)
WO (1) WO2018089914A1 (enrdf_load_stackoverflow)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3075598A1 (en) * 2017-09-14 2019-03-21 Janssen Biopharma, Inc. Galnac derivatives
WO2019240504A1 (en) * 2018-06-12 2019-12-19 Am Sciences Co., Ltd. Modified oligonucleotides for inhibition of target gene expression
WO2019240503A1 (ko) * 2018-06-12 2019-12-19 주식회사 에이엠사이언스 B형 간염 예방 또는 치료용 조성물
JP7653997B2 (ja) * 2019-12-19 2025-03-31 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
JP2023506540A (ja) * 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
CN113493855B (zh) * 2020-03-19 2023-12-26 首都医科大学附属北京佑安医院 一种基于RAA-CRISPR-cas13a检测HBV cccDNA的试剂盒
TW202223089A (zh) * 2020-07-27 2022-06-16 美商艾利格斯醫療公司 與hbv結合之寡核苷酸及使用方法
CN116157522A (zh) * 2020-08-21 2023-05-23 豪夫迈·罗氏有限公司 A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
CN118667808B (zh) * 2023-08-22 2025-04-18 浙江柏拉阿图医药科技有限公司 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513887A (ja) * 1999-09-10 2003-04-15 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用
JP2012223202A (ja) * 2004-12-22 2012-11-15 Alnylam Pharmaceuticals Inc 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
WO2016077321A1 (en) * 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016176745A1 (en) * 2015-05-06 2016-11-10 Benitec Biopharma Limited Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887906B1 (en) 1997-07-01 2005-05-03 Isispharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
AR028149A1 (es) * 1999-07-08 2003-04-30 Innogenetics Nv Deteccion de la resistencia a los farmacos contra la hepatitis b
RS61447B1 (sr) * 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
CN114058617A (zh) * 2013-05-01 2022-02-18 Ionis制药公司 缀合反义化合物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513887A (ja) * 1999-09-10 2003-04-15 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用
JP2012223202A (ja) * 2004-12-22 2012-11-15 Alnylam Pharmaceuticals Inc 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
WO2016077321A1 (en) * 2014-11-10 2016-05-19 Alnylam Pharmaceuticals, Inc. Hepatitis b virus (hbv) irna compositions and methods of use thereof
WO2016176745A1 (en) * 2015-05-06 2016-11-10 Benitec Biopharma Limited Reagents for treatment of hepatitis b virus (hbv) infection and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INT. J. MOL. SCI. 2015,16,17589-17610, JPN6021034320, ISSN: 0004587936 *

Also Published As

Publication number Publication date
US20180179542A1 (en) 2018-06-28
CN110234763A (zh) 2019-09-13
AU2017356221A1 (en) 2019-05-30
IL266525A (en) 2019-07-31
CA3043637A1 (en) 2018-05-17
WO2018089914A1 (en) 2018-05-17
TW201831684A (zh) 2018-09-01
KR20190076050A (ko) 2019-07-01
EP3538654A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
JP2019533472A (ja) Ｈｂｖ ｃｃｃｄｎａのオリゴヌクレオチド標的化戦略
CN109843902B (zh) 用于B型肝炎病毒感染的RNAi剂
JP5892938B2 (ja) Ｈｂｖアンチセンス阻害剤
TWI872048B (zh) 用於Ｂ型肝炎病毒感染之ＲＮＡｉ劑
JP6922030B2 (ja) Ｂ型肝炎およびｄ型肝炎ウイルス感染の治療のための方法
TW201446791A (zh) 用於調節mir-122之微小rna化合物及方法
AU2014205544B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2023093896A1 (zh) 用于抑制乙型肝炎病毒(hbv)蛋白表达的组合物和方法
HK40014091A (en) Oligonucleotide targeting strategy for hbv cccdna
HK40062579A (en) Rnai agents for hepatitis b virus infection
HK40009627B (en) Rnai agents for hepatitis b virus infection
EA044937B1 (ru) АГЕНТЫ РНКи ПРОТИВ ИНФЕКЦИИ, ВЫЗВАННОЙ ВИРУСОМ ГЕПАТИТА В
HK40009627A (en) Rnai agents for hepatitis b virus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211223

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220510